Background: Protein arginine methylation is an important posttranslational modification in eukaryotic cells, which has been implicated in RNA processing and trafficking, receptor mediated signaling, and transcription. PRMT4, also known as CARM1, catalyses the mono- and asymmetric dimethylation of arginine residues in several proteins involved in DNA packaging, transcription regulation and mRNA stability. PRMT4 methylates R2, R17 and R26 of histone H3 and cooperates synergistically with p300/CBP and p160 coactivators to enhance transcriptional activation by nuclear receptors. PRMT4 also methylates several non-histone proteins, including transcriptional coactivators such as p300/CBP, splicing factors and RNA binding proteins. PRMT4 is also a co-activator of p53, facilitating p53-mediated transcription through the methylation of histones H3 and H4.
Description: Rabbit polyclonal to PRMT4(phospho S228)
Immunogen: A synthesized phosphopeptide derived from human PRMT4 around the phosphorylation site of serine 228 (V-K-SP-N-N).
Specificity: ·Reacts with Human, Mouse, Pig, Dog and Rat.
·Isotype: IgG
Application: ·Western blotting: 1/500-1000. Predicted Mol wt: 63 kDa;
·Immunohistochemistry (Frozen/paraffin tissue section): 1/100-500;
·Immunocytochemistry: 1/200-500;
·ELISA: 1/500;
· Optimal working dilutions must be determined by the end user.
